

Wall Teichoic Acid Glycosylation Governs *Staphylococcus aureus* Nasal Colonization

Volker Winstel,^{a,b} Petra Kühner,^{a,b} Ferdinand Salomon,^{a,b} Jesper Larsen,^c Robert Skov,^c Wolfgang Hoffmann,^d Andreas Peschel,^{a,b} Christopher Weidenmaier^{a,b}

Cellular and Molecular Microbiology Division, Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen, Germany^a; German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany^b; Microbiology and Infection Control, Statens Serum Institute, Copenhagen, Denmark^c; Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany^d

ABSTRACT Nasal colonization by the human pathogen *Staphylococcus aureus* is a major risk factor for hospital- and community-acquired infections. A key factor required for nasal colonization is a cell surface-exposed zwitterionic glycopolymer, termed wall teichoic acid (WTA). However, the precise mechanisms that govern WTA-mediated nasal colonization have remained elusive. Here, we report that WTA GlcNAcylation is a pivotal requirement for WTA-dependent attachment of community-acquired methicillin-resistant *S. aureus* (MRSA) and emerging livestock-associated MRSA to human nasal epithelial cells, even under conditions simulating the nutrient composition and dynamic flow of nasal secretions. Depending on the *S. aureus* strain, WTA O-GlcNAcylation occurs in either α or β configuration, which have similar capacities to mediate attachment to human nasal epithelial cells, suggesting that many *S. aureus* strains maintain redundant pathways to ensure appropriate WTA glycosylation. Strikingly, a lack of WTA glycosylation significantly abrogated the ability of MRSA to colonize cotton rat nares *in vivo*. These results indicate that WTA glycosylation modulates *S. aureus* nasal colonization and may help to develop new strategies for eradicating *S. aureus* nasal colonization in the future.

IMPORTANCE Nasal colonization by the major human pathogen *Staphylococcus aureus* is a risk factor for severe endogenous infections and contributes to the spread of this microbe in hospitals and the community. Here, we show that wall teichoic acid (WTA) O-GlcNAcylation is a key factor required for *S. aureus* nasal colonization. These data provide a mechanistic explanation for the capacity of WTA to modulate *S. aureus* nasal colonization and may stimulate research activities to establish valuable strategies to eradicate *S. aureus* nasal colonization in high-risk hospitalized patients and in the general community.

Received 15 April 2015 Accepted 8 June 2015 Published 30 June 2015

Citation Winstel V, Kühner P, Salomon F, Larsen J, Skov R, Hoffmann W, Peschel A, Weidenmaier C. 2015. Wall teichoic acid glycosylation governs *Staphylococcus aureus* nasal colonization. mBio 6(4):e00632-15. doi:10.1128/mBio.00632-15.

Editor Steven J. Projan, MedImmune

Copyright © 2015 Winstel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported license, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited. Address correspondence to Andreas Peschel, andreas.peschel@uni-tuebingen.de.

S*taphylococcus aureus* is one of the most important bacterial pathogens in hospital- and community-acquired (CA) infections. *S. aureus* colonizes the anterior nares of approximately 20 to 30% of the healthy population asymptomatically. Nasal colonization by *S. aureus* has been found to be a major risk factor for severe endogenous infections and contributes to the transmission and spread of *S. aureus* in hospitals (1, 2).

S. aureus nasal colonization is a complex and multifactorial process which is understood only incompletely. Both microbial and human host factors appear to mediate and modulate *S. aureus* nasal colonization. Host factors shaping nasal colonization include, for example, the presence of hemoglobin in nasal secretions (3), altered expression of antimicrobial peptides in human skin (4, 5), nutrient limitation (6), and polymorphisms in immunomodulatory mediators or receptors (7, 8). Equally importantly, *S. aureus* nasal colonization and stable persistence require bacterial factors which govern efficient attachment to squamous or ciliated epithelial cells located in different areas of the nasal cavity (9, 10). In particular, various *S. aureus* proteins belonging to the group of "microbial surface components recognizing adhesive matrix mol-

ecules" (MSCRAMMs) have been shown to mediate interaction with components of human desquamated nasal epithelial cells (11-13), above all, with cytokeratin-10 and loricrin-binding clumping factor B (ClfB) (14, 15) and iron-regulated surface determinant A (IsdA) (16). *isdA* and *clfB* are upregulated during nasal colonization in humans and in vivo models of experimental colonization compared to in vitro growth in broth cultures (17-19). S. aureus mutants lacking ClfB cannot persist in the human nose over a longer time period, underscoring the key role of ClfB in S. aureus nasal long-term colonization (20). However, during early-stage colonization, *clfB* and *isdA* are usually expressed only at low levels. In contrast, genes required for the biosynthesis of another cell wall-anchored macromolecule, designated wall teichoic acid (WTA), are upregulated during this period (17, 18). Typically, S. aureus strains, including methicillin-resistant S. aureus (MRSA) and highly virulent clones such as American pandemic clone USA300, synthesize WTA polymers composed of 11 to 40 ribitolphosphate (RboP) repeating units modified with three tailoring modifications, D-alanine, α -O-N-acetylglucosamine (GlcNAc), and β -O-GlcNAc (10, 21). Interestingly, S. aureus mutants lacking

TABLE 1	Distribution	of WTA	glycosylt	ransferases	TarM	and	TarS	in
nasal S. av	<i>ireus</i> isolates							

	Value for WTA glycosyltransferase-encoding gene(s):				
Parameter	tarM	tarS	<i>tarM</i> and <i>tarS</i>		
No. of gene-positive nasal isolates ^a Rate of gene-positive nasal isolates (%) ^b	25 35.7	70 100	25 35.7		

^{*a*} A total of 70 *S. aureus* isolates obtained from healthy carriers or hospital patients was tested. *spa* typing revealed 49 different *spa* types associated with at least 15 different sequence types (see also Table S1 in the supplemental material).

 b Values (%) were calculated by dividing the number of positive isolates by the total number of tested isolates.

WTA lost their capability to colonize cotton rat nares, while mutants that lost the ability to modify teichoic acids by D-alanylation (WTA and lipoteichoic acid) exhibited reduced colonization. Both types of mutants feature strongly reduced binding capacities to living human primary nasal epithelial cells (22, 23). A recently discovered type F scavenger receptor (SREC-I), present on human nasal epithelial cells, governs *S. aureus* nasal colonization via charge-dependent interaction with WTA polymers, indicating that the D-alanine modification of WTA contributes to *S. aureus* nasal colonization (24). However, the role of the WTA aminosugar modification with GlcNAc in nasal colonization, which occurs in two different stereochemical configurations (α - and β -O linkages), remains elusive.

Here, we analyzed the role of *S. aureus* WTA O-GlcNAcylation during nasal colonization and reveal molecular determinants that contribute to WTA-mediated *S. aureus* nasal colonization *in vitro* and *in vivo*.

RESULTS AND DISCUSSION

S. aureus nasal isolates encode WTA glycosyltransferases. Two recently discovered enzymes, the α -O-GlcNAc WTA glycosyltransferase TarM and the β -O-GlcNAc glycosyltransferase TarS, can glycosylate S. aureus WTA (25, 26). With only very few exceptions, tarS is present in all sequenced S. aureus genomes. In contrast, tarM is absent in certain clonal complexes (CC), for example, in the emerging CC398, which includes livestock-associated MRSA clones (LA-MRSA CC398). This raises the question of whether TarM-dependent WTA α -O-GlcNAcylation may play a role in S. aureus host tropism (21).

Here, 70 isolates from a collection of genetically diverse nasal *S. aureus* isolates (49 different *spa* types associated with at least 15 different sequence types) obtained from healthy volunteers or hospital patients were typed by PCR for the presence or absence of *S. aureus* WTA-glycosyltransferase-encoding genes. All tested nasal isolates bore *tarS*, while only a minority (35.7%) of these strains bore both *tarM* and *tarS*, indicating that, in principle, nasal *S. aureus* strains should be capable of glycosylating WTA (Table 1).

Impact of nasal growth conditions on *S. aureus* WTA glycosylation. In order to analyze if such nasal strains indeed have glycosylated WTA, their capacity to bind WTA GlcNAcdependent bacteriophages (phages) such as Φ 11 (27) was investigated upon growth in a recently developed synthetic nasal medium (SNM3, containing 0.2 mM bipyridine) providing suitable conditions for simulating the nasal habitat (6). All tested SNM3-grown *S. aureus* strains were susceptible to phage Φ 11, and, interestingly, the phage adsorption rate was increased compared even to that seen with bacteria cultivated in standard laboratory media (Fig. 1A and B). Moreover, even though *tarM* was downregulated in SNM3, the gene for the TarS β -O-GlcNAc WTA glycosyltransferase was upregulated in community-associated MRSA (CA-MRSA; *tarM*- and *tarS*-positive) strain USA300 during the logarithmic- and stationary-growth phases in SNM3 compared to the level seen in bacteria grown in rich B-medium (BM) (Fig. 1C). Thus, WTA polymers are most probably glycosylated under nasal growth conditions but may differ with respect to the type of GlcNAc linkage.

WTA glycosylation affects interaction of MRSA with epithelial cells. Next, the impact of WTA glycosylation on nasal colonization and binding to human epithelial cells was clarified by using various S. aureus isolates, including tarM- and tarS-containing CA-MRSA strain USA300 and the RN4220 laboratory strain as well as LA-MRSA CC398 strain 82086 naturally lacking tarM plus corresponding mutants completely lacking WTA glycosylation. Importantly, a lack of WTA glycosylation did not alter expression levels of MSCRAMMs such as ClfB, SdrC, SdrD, IsdA, and SasG, which are known to interact with components of nasal squames (see Fig. S1A in the supplemental material). Accordingly, the ability of S. aureus variants lacking WTA glycosylation to interact with extracellular matrix proteins such as cytokeratin-10, fibronectin, and fibring en was equal to that of the wild-type strain, indicating that matrix-protein binding MSCRAMMs are fully functional in the mutants (see Fig. S1B to D).

However, the absence of WTA glycosylation caused a strong reduction in the binding capacity of S. aureus to living human airway epithelial cells (A549) and to primary epithelial cells derived from cotton rat (CRNEC) or human nares (HNEpC) (Fig. 2; see also Fig. S2 in the supplemental material). Complementation by either the TarM α -O-GlcNAc WTA glycosyltransferase or the TarS β -O-GlcNAc WTA glycosyltransferase restored the binding capacity of WTA glycosylation-deficient mutants to levels comparable to those seen with the corresponding parental strains, suggesting that WTA glycosylation is required for efficient interaction with nasal epithelial cells but that the stereochemistry of WTA glycosylation is of minor importance for this interaction. Indeed, the binding capacity of S. aureus USA300 mutants, which still glycosylate WTA but lack one of the two glycosyltransferases (TarM or TarS), to A549 cells or to primary nasal epithelial cells was not affected (see Fig. S3). Similar effects were observed when adherence to primary nasal epithelial cells was monitored under mild shear forces mimicking the dynamic movement of nasal mucus, thereby emphasizing the importance of WTA-GlcNAcylation for interaction with epithelial cells (Fig. 3). However, S. aureus mutants completely lacking WTA polymers ($\Delta tagO$) were also strongly abrogated in binding to epithelial cells compared to the parental strain, which is in agreement with previous reports (22, 23) (Fig. 2 and 3B and C). The more pronounced effect in the $\Delta tagO$ mutant than in the glycosylation-deficient mutants may result from the absence of zwitterionic WTA repeating units and their GlcNAcylation, which both appear to be important for interaction with epithelial cell receptors. Together, these findings indicate that backbone glycosylation is an important component



FIG 1 Impact of nasal growth conditions on WTA composition and WTA glycosylation. (A and B) *S. aureus* susceptibility to the WTA GlcNAc-dependent bacteriophage Φ 11 (A) along with Φ 11 adsorption levels (B). (C) qRT-PCR analysis of WTA glycosyltransferase gene expression levels in *S. aureus* USA300. mRNA was isolated from lag-, log-, or stationary (stat.)-phase-grown bacteria. For bacteriophage susceptibility and adsorption analysis or analysis of gene expression levels, strains were grown under rich conditions (B-medium [BM]; white columns) or nasal growth conditions (SNM3 [containing 0.2 mM bipyridine]; black columns). Values are given as means and standard deviations (SD; n = 3 to 6). Statistically significant differences calculated using an unpaired two-tailed Student's *t* test are indicated as follows: ns (not significant), P > 0.05; *, P < 0.05, **, P < 0.01; ***, P < 0.001.

of WTA polymers required for efficient interaction with human epithelial cells.

WTA glycosylation affects S. aureus nasal colonization in vivo. Finally, the impact of WTA glycosylation on S. aureus nasal colonization was analyzed by using a cotton rat in vivo colonization model (22, 28). Cotton rat nares share histological properties with human nares and permit stable long-term nasal colonization with S. aureus (29). Moreover, cotton rats are susceptible to various human respiratory bacterial pathogens, thereby representing an excellent in vivo nasal colonization model (30). Notably, lack of WTA glycosylation significantly abrogated S. aureus nasal colonization in the cotton rat model 3 days after inoculation (Fig. 4). Since absence of WTA glycosylation did not affect S. aureus susceptibility to killing by antimicrobial peptides such as the cathelicidin LL-37 (see Fig. S4 in the supplemental material) or growth in various laboratory media, including the SNM3 synthetic nasal medium (see Fig. S5), the reduced nasal colonization capacity is very likely due to diminished interaction with nasal epithelial cells. Thus, WTA glycosylation affects S. aureus nasal colonization in vivo.

In summary, WTA glycosylation represents a key requirement for efficient S. aureus nasal colonization that most probably operates by modulating interaction with nasal epithelial cells. Since the majority of tested nasal S. aureus isolates encoded only tarS and not *tarM*, it is tempting to speculate that β -O-GlcNAcylated WTA might be more critical than α -O-GlcNAcylated WTA for S. aureus during nasal colonization. Nevertheless, WTA interaction with epithelial cells does not seem to depend on a specific stereochemistry of GlcNAc. The different types of WTA glycosylation might be more relevant for shaping other host-pathogen interaction processes such as activation of the human complement system via WTA B-O-GlcNAc-specific antibodies or mannose-binding lectin (31). However, WTA-deficient mutants exhibited even more diminished binding capacities to nasal epithelial cells than WTA glycosylation-deficient mutants, suggesting that the zwitterionic WTA repeating units and their GlcNAcylation are probably of the same importance for interaction with host cell receptors. While it has been demonstrated before that the zwitterionic properties of WTA polymers depending on free aminogroups of the D-alanine substituents govern interaction with the hu-



FIG 2 WTA glycosylation affects interaction of MRSA with epithelial cells. Data represent binding capacities of *S. aureus* variants to A549 lung epithelial cells (MOI30) (A), cotton rat nasal epithelial primary cells (CRNEC) (MOI20) (B), or human nasal epithelial primary cells (HNEpC) (MOI30) (C) under static conditions. The binding capacities of various strains encompassing the CA-MRSA USA300 strain and a LA-MRSA CC398 strain (82086) to confluent epithelial cell monolayers were analyzed. The *S. aureus* wild-type (w.t.) strain and strains lacking WTA ($\Delta tagO$) or WTA glycosylation ($\Delta tarM$ $\Delta tarS$ [$\Delta M\Delta S$] or $\Delta tarS$, [ΔS], LA-MRSA CC398 strain 82086) and the complemented mutants ($\Delta M\Delta S$ *c-tarS*, Or ΔS *c-tarS*, LA-MRSA CC398 strain 82086) are indicated. Values are given as means and standard deviations (SD; n = 3 to 4). Statistically significant differences calculated using one-way analysis of variance (ANOVA) with Bonferroni's multiple-comparison test are indicated as follows: ns (not significant), P > 0.05; *, P < 0.05, **, P < 0.01; ***, P < 0.001; ***, P < 0.001.

man scavenger receptor SREC-I in a charge-dependent manner (24), the identity of the host cell receptor responsible for interaction with WTA glycosyl residues remains unclear. Since SREC-I does not exhibit an obvious carbohydrate recognition domain, other human scavenger receptors have to be considered in the future for WTA glycosylation-dependent binding to epithelial cells. Consequently, antibody-based targeting of these receptors or their bacterial ligands, potentially in combination with nasal elimination of *S. aureus* by the antibiotic mupirocin (32), might become a suitable strategy for eradicating *S. aureus* nasal colonization in high-risk hospitalized patients and in the general community.

MATERIALS AND METHODS

Bacterial strains and growth media. All bacterial strains listed in Table S1 in the supplemental material were grown in lysogeny broth (Becton, Dickinson), B-medium (1% tryptone, 0.5% yeast extract, 0.5% NaCl, 0.1% K_2 HPO₄, 0.1% glucose), or Mueller-Hinton broth (MHB) or in a recently described synthetic nasal medium (SNM3, containing 0.2 mM bipyridine) (6) at permissive temperatures and were supplemented with the



FIG 3 WTA glycosylation mediates adherence to primary epithelial cells under dynamic flow conditions. (A) Principle of flow-chamber-based attachment assays mimicking dynamic nasal conditions. (B and C) The binding capacities of *S. aureus* variants to monolayers of confluent cotton rat nasal epithelial primary cells (CRNEC) (MOI60) (B) or human nasal epithelial primary cells (HNEpC) (MOI60) (C) under conditions of mild shear stress were analyzed. The *S. aureus* USA300 wild-type (w.t.) strain, strains lacking WTA ($\Delta tagO$) or WTA glycosylation ($\Delta tarM \Delta tarS [\Delta M\Delta S]$), and the complemented mutants ($\Delta M\Delta S$ *c-tarM* and $\Delta M\Delta S$ *c-tarS*) are indicated. Values are given as means and standard deviations (SD; n = 3 to 4). Statistically significant differences calculated using one-way ANOVA with Bonferroni's multiple-comparison test are indicated as follows: ns (not significant), P > 0.05; *, P < 0.05; **, P < 0.001; ****, P < 0.001.

appropriate antibiotics (chloramphenicol [10 μ g/ml], streptomycin [250 to 500 μ g/ml], and ampicillin [100 μ g/ml]). Growth characteristics were monitored at 37°C.

Molecular genetic methods. For deletion of *tarM*, *tarS*, *tarM* and *tarS*, *or tagO* in *S. aureus* USA300 or in a LA-MRSA CC398 strain (82086), a



FIG 4 WTA glycosylation affects *S. aureus* nasal colonization *in vivo*. Cotton rats were intranasally challenged with the *S. aureus* USA300 wild-type (w.t.) strain and the USA300 $\Delta tarM \Delta tarS (\Delta M\Delta S)$ mutant lacking WTA glycosylation. Colonization status was analyzed 3 days after bacterial instillation. Statistically significant differences calculated using a D'Agostino and Pearson omnibus normality test and a subsequent Mann-Whitney test are indicated as follows: *, P < 0.05.

previously described Escherichia coli-S. aureus shuttle vector, pKOR1, was used (33). For deletion of srtA, an E. coli-S. aureus shuttle vector, pIMAY, was used (34). Gene disruption via pKOR1 or pIMAY was performed via allelic replacement as described before (33, 34). Briefly, knockout plasmids were isolated from appropriate E. coli strains, transformed into electrocompetent S. aureus RN4220 cells, reisolated, and subsequently electroporated in a target strain (USA300 or 82086). Electroporation conditions were described elsewhere (35). Knockout plasmids were integrated onto the genome of target strains at permissive temperatures (for pKOR1, 43°C; for pIMAY, 37°C) and in the presence of chloramphenicol (10 μ g/ml). Following plasmid integration, a counterselection step was performed at 30°C using anhydrotetracycline (1 µg/ml). Resulting colonies were patched onto BM agar plates with or without chloramphenicol (10 µg/ml) and screened for plasmid loss. Chloramphenicol-sensitive colonies were screened via PCR to confirm gene deletion. The S. aureus RN4220 variants were described elsewhere (35). For complementation studies, the previously described pRB474 E. coli-S. aureus shuttle vector was used (36).

The presence or absence of *S. aureus* WTA glycosyltransferaseencoding genes *tarM* and *tarS* in nasal *S. aureus* isolates was verified via PCR using the gene-specific primers listed in Table S2 in the supplemental material. *spa* typing was performed as described previously (37). Briefly, the *spa* repeat region was amplified using the published primers listed in Table S2, sequenced, and analyzed using Ridom StaphType 1.5.21 software (37).

Cell culture. Primary human nasal epithelial cells (HNEpC) were purchased from PromoCell (PromoCell, Heidelberg, Germany) and grown in airway epithelial growth medium (PromoCell) according to the manufacturer's instructions. Primary cotton rat nasal epithelial cells (CRNEC) were isolated from cotton rat nares and cultivated in Dulbecco's modified Eagle's medium-F12 (DMEM-F12) (Gibco-BRL) supplemented with 100 U/ml penicillin, 100 μ g/ml streptomycin, 10% heat-inactivated fetal bovine serum, and 2 mM glutamine as previously described (24). A549

lung epithelial cells (American Type Culture Collection [ATCC CCL-185]) were purchased from the ATCC and grown in DMEM-F12 medium (Gibco-BRL) supplemented with 100 U/ml penicillin, 100 μ g/ml streptomycin, 10% heat-inactivated fetal bovine serum, and 2 mM glutamine. Epithelial cells were grown at 37°C under 5% CO₂.

Interaction of S. aureus with epithelial cells. Adherence of S. aureus to epithelial cells was analyzed as described elsewhere (22). Briefly, approximately 5 \times 10⁴ A549, 2.5 \times 10⁴ CRNEC, or 2.5 \times 10⁴ HNEpC cells were seeded to 24-well culture plates and grown at 37°C under 5% CO₂ in appropriate cell culture media. Bacterial overnight cultures grown in B-medium at 37°C were diluted in MHB and grown at 37°C to the mid-logarithmic-growth phase, washed three times with phosphate-buffered saline (PBS), and labeled with fluorescein isothiocyanate (FITC; 0.1 mg/ml) for 1 h at 37°C. FITClabeled bacteria were washed three times with PBS and resuspended in RPMI medium (Sigma, St. Louis, MO, USA). Bacterial cell numbers were adjusted using a Neubauer chamber. Confluent epithelial cell monolayers were washed twice with RPMI medium and inoculated with FITC-labeled bacteria for 1 h at 37°C under 5% CO₂. Parameters of multiplicities of infection (MOI) were chosen in a strain-dependent manner and are individually given in the corresponding figure legends. Subsequently, epithelial cell monolayers were washed twice with RPMI and subsequently with PBS. Cells were fixed at room temperature for 10 min using 3.5% paraformaldehyde (PFA)-PBS. PFA was removed, and wells were coated with 1 ml PBS. No morphological changes were observed after this procedure. Adherent bacteria per 0.1 mm² were counted (in at least 6 random fields of 0.1 mm²) using a fluorescence microscope

Adherence under shear stress conditions was monitored in chamber slides (μ -Slide VI0.4; ibidi, Martinsried, Germany) as described before (24) with minor modifications. Briefly, approximately 2 × 10⁴ HNEpC or 2 × 10⁴ CRNEC cells were seeded to chamber slides and cultivated as described before. Confluent epithelial cell monolayers were washed twice with RPMI medium. Subsequently, peristaltic pumps (Amersham) were used for infection (20 min) with FITC-labeled bacteria at a flow rate of 1 ml/h, mimicking mild shear stress conditions at 0.3 dynes/cm². MOI parameters are given in the corresponding figure legends. Cell monolayers were washed in two consecutive steps using RPMI medium and PBS and fixed as described before. Adherent bacteria per 0.1 mm² were counted (in at least 8 random fields of 0.1 mm²) using a fluorescence microscope.

Adherence to extracellular matrix proteins. Adherence to extracellular matrix proteins was analyzed as described elsewhere (23) with minor modifications. Briefly, 96-well microtiter plates were coated with keratin (50 µg/well), fibrinogen (2.5 µg/well), or fibronectin (15 µg/well) (all obtained from Sigma, St. Louis, MO, USA) mixed in sodium carbonate buffer (50 mM, pH 9.6) overnight at 4°C. Next, wells were blocked by using 100 µl 2% bovine serum albumin (BSA)–PBS for 2 h at room temperature. Wells were washed with 200 µl PBS and incubated with 100 µl bacteria (5 × 10° CFU/ml) for 1.5 h at 37°C. Wells were washed three times with 200 µl PBS. Bacteria were stained using 100 µl crystal violet (2 mg/ml in PBS) for 2 min at room temperature. Subsequently, wells were washed five times with 400 µl PBS. A 100 µl volume of (70%) ethanol was added to each well, and the absorbance at 600 nm (A_{600}) was determined.

Experiments with phages. Phage Φ 11 susceptibility of *S. aureus* was analyzed as described before (35). When bacteria were grown under nasal growth conditions using SNM3 (containing 0.2 mM bipyridine), phage susceptibility was analyzed on solid SNM3 agar overlaid with SNM3 soft agar (0.4% agar). Phage Φ 11 adsorption to various *S. aureus* isolates grown in rich medium (B-medium) or in SNM3 (containing 0.2 mM bipyridine) was analyzed as described previously (35). Briefly, phage Φ 11 was propagated on the *S. aureus* RN4220 wild-type strain and used for adsorption to test strains was calculated by determining the number of PFU of unbound phages in supernatants and subtracting that value from the total number of input PFU as a ratio to the total number of input PFU.

RNA isolation and preparation. B-medium overnight cultures were diluted in fresh media (B-medium or SNM3 [containing 0.2 mM bipyri-

dine]) and grown at 37°C. Bacteria were harvested in the lag-, log-, or stationary-growth phase and subsequently resolved in 1 ml TRIzol (Invitrogen/Life Technologies, Karlsruhe, Germany). Bacteria were mechanically disrupted with 0.5 ml zirconia-silica beads (Carl-Roth, Karlsruhe, Germany) (0.1 mm in diameter) using a FastPrep 24 homogenizer (MP Biomedicals) (2 cycles of 20 s at a speed of 6.5 m/s). Samples were stored at -80°C or subsequently used for further preparation. Chloroform (200 μ l) was added, and samples were thoroughly mixed for 60 s and incubated for 3 min at room temperature. Samples were centrifuged $(12,000 \times g, 15 \text{ min}, 4^{\circ}\text{C})$, and the supernatant was mixed with 500 μ l isopropanol. Samples were incubated for 10 min at room temperature and centrifuged (12,000 \times g, 30 min, 4°C). The pellet was washed with 500 μ l (70%) ethanol, and the sample was centrifuged at 7,500 \times g for 5 min (4°C). The pellet was air dried and dissolved in 50 μ l nuclease-free water. After incubation at 55°C for 10 min, the sample was mixed well for 4 min and 5 μ g RNA was digested with DNase I (Roche) and stored at -80° C.

qRT-PCR. The primers used for quantitative real-time PCR (qRT-PCR) are listed in Table S2 in the supplemental material. RNA was transcribed into cDNA, and qRT-PCR was performed according to the instructions of the manufacturer using Brilliant II SYBR green 1-Step master mix (Agilent). Relative quantifications were analyzed using Roche's LightCycler 480 II system. Transcription levels of target genes analyzed in this study were normalized against the expression of the *gyrB* housekeeping gene (38).

S. aureus killing by antimicrobial peptides. Killing by antimicrobial peptides was analyzed as described before (22) with minor modifications. Briefly, S. aureus overnight cultures were diluted in MHB and grown to the mid-logarithmic-growth phase. Cells were washed 3 times in potassium phosphate buffer (PPB) (pH 7.5) containing 0.005% human serum albumin (HSA) (PPB-HSA). Approximately 2.0×10^5 bacteria (in PPB-BSA) were treated with 10 µg/ml LL-37 (Sigma, St. Louis, MO, USA). Killing was analyzed over a time period of 180 min. Each reaction was stopped by addition of 250 µl ice-cold PPB-BSA. Serial dilutions were plated on appropriate agar plates to analyze killing by determination of CFU, and the results are given as a ratio to the total number of input CFU.

Cotton rat nasal colonization model. For analysis of *S. aureus* nasal colonization *in vivo*, a cotton rat model was used (22). Cotton rats continuously received drinking water containing 2.5 mg/ml streptomycin to reduce natural nasal flora 3 days before the experiment. The cotton rats were anesthetized and instilled intranasally with 10 μ l of 1 × 10⁷ CFU of the *S. aureus* USA300 wild type or USA300 $\Delta tarM \Delta tarS$. Three days after bacterial instillation, animals were euthanized and nares were removed surgically. Nares were subjected to vortex mixing for 30 s in 1 ml PBS containing 0.5% Tween 20. Serial dilutions were plated on appropriate agar plates to calculate nasal colonization data.

Ethics statement. All animal experiments were performed in strict accordance with the German regulations of the Gesellschaft für Versuchstierkunde/Society for Laboratory Animal Science (GV-SOLAS) and the European Health Law of the Federation of Laboratory Animal Science Associations (FELASA). The protocol was approved by the Regierungspräsidium Tübingen, Tübingen, Germany (permit no. T1/10).

Statistical analysis. Statistical analysis was performed by using Graph-Pad Prism (GraphPad Software, Inc., La Jolla, USA; version 5.04). Statistically significant differences were calculated by using appropriate statistical methods as indicated. *P* values of ≤ 0.05 were considered significant.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.00632-15/-/DCSupplemental.

Figure S1, TIF file, 0.3 MB. Figure S2, TIF file, 0.2 MB. Figure S3, TIF file, 0.2 MB. Figure S4, TIF file, 0.1 MB. Figure S5, TIF file, 0.5 MB. Table S1, DOCX file, 0.04 MB. Table S2, DOCX file, 0.02 MB.

ACKNOWLEDGMENTS

We thank Bernhard Krismer and Matthias Marschal for providing nasal *S. aureus* isolates, Berit Schulte for help with *spa* typing, and Alexander Zipperer for help with cotton rats.

This work was supported by grants from the German Research Council (TRR34, TRR156, and SFB766) and from the German Center for Infection Research (DZIF) to A.P. and C.W.

REFERENCES

- Von Eiff C, Becker K, Machka K, Stammer H, Peters G. 2001. Nasal carriage as a source of *Staphylococcus aureus* bacteremia. N Engl J Med 344:11–16. http://dx.doi.org/10.1056/NEJM200101043440102.
- Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in *Staphylo-coccus aureus* infections. Lancet Infect Dis 5:751–762. http://dx.doi.org/ 10.1016/S1473-3099(05)70295-4.
- Pynnonen M, Stephenson RE, Schwartz K, Hernandez M, Boles BR. 2011. Hemoglobin promotes *Staphylococcus aureus* nasal colonization. PLoS Pathog 7:e1002104. http://dx.doi.org/10.1371/journal.ppat.1002104.
- Nurjadi D, Herrmann E, Hinderberger I, Zanger P. 2013. Impaired beta-defensin expression in human skin links DEFB1 promoter polymorphisms with persistent *Staphylococcus aureus* nasal carriage. J Infect Dis 207:666–674. http://dx.doi.org/10.1093/infdis/jis735.
- Zanger P, Nurjadi D, Vath B, Kremsner PG. 2011. Persistent nasal carriage of *Staphylococcus aureus* is associated with deficient induction of human beta-defensin 3 after sterile wounding of healthy skin *in vivo*. Infect Immun 79:2658–2662. http://dx.doi.org/10.1128/IAI.00101-11.
- Krismer B, Liebeke M, Janek D, Nega M, Rautenberg M, Hornig G, Unger C, Weidenmaier C, Lalk M, Peschel A. 2014. Nutrient limitation governs *Staphylococcus aureus* metabolism and niche adaptation in the human nose. PLoS Pathog 10:e1003862. http://dx.doi.org/10.1371/ journal.ppat.1003862.
- Van den Akker EL, Nouwen JL, Melles DC, van Rossum EF, Koper JW, Uitterlinden AG, Hofman A, Verbrugh HA, Pols HA, Lamberts SW, van Belkum A. 2006. *Staphylococcus aureus* nasal carriage is associated with glucocorticoid receptor gene polymorphisms. J Infect Dis 194: 814–818. http://dx.doi.org/10.1086/506367.
- Emonts M, Uitterlinden AG, Nouwen JL, Kardys I, Maat MP, Melles DC, Witteman J, Jong PT, Verbrugh HA, Hofman A, Hermans PW, Belkum A. 2008. Host polymorphisms in interleukin 4, complement factor H, and C-reactive protein associated with nasal carriage of *Staphylococcus aureus* and occurrence of boils. J Infect Dis 197:1244–1253. http:// dx.doi.org/10.1086/533501.
- Foster TJ, Geoghegan JA, Ganesh VK, Höök M. 2014. Adhesion, invasion and evasion: the many functions of the surface proteins of *Staphylococcus aureus*. Nat Rev Microbiol 12:49–62. http://dx.doi.org/10.1038/ nrmicro3161.
- Weidenmaier C, Peschel A. 2008. Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. Nat Rev Microbiol 6:276–287. http://dx.doi.org/10.1038/nrmicro1861.
- Corrigan RM, Rigby D, Handley P, Foster TJ. 2007. The role of *Staphylococcus aureus* surface protein SasG in adherence and biofilm formation. Microbiology 153:2435–2446. http://dx.doi.org/10.1099/mic.0.2007/ 006676-0.
- 12. Roche FM, Meehan M, Foster TJ. 2003. The *Staphylococcus aureus* surface protein SasG and its homologues promote bacterial adherence to human desquamated nasal epithelial cells. Microbiology 149:2759–2767. http://dx.doi.org/10.1099/mic.0.26412-0.
- Corrigan RM, Miajlovic H, Foster TJ. 2009. Surface proteins that promote adherence of *Staphylococcus aureus* to human desquamated nasal epithelial cells. BMC Microbiol 9:22. http://dx.doi.org/10.1186/1471 -2180-9-22.
- Mulcahy ME, Geoghegan JA, Monk IR, O'Keeffe KM, Walsh EJ, Foster TJ, McLoughlin RM. 2012. Nasal colonisation by *Staphylococcus aureus* depends upon clumping factor B binding to the squamous epithelial cell envelope protein loricrin. PLoS Pathog 8:e1003092. http://dx.doi.org/ 10.1371/journal.ppat.1003092.
- O'Brien LM, Walsh EJ, Massey RC, Peacock SJ, Foster TJ. 2002. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell Microbiol 4:759–770. http://dx.doi.org/10.1046/j.1462-5822.2002.00231.x.

- Clarke SR, Brummell KJ, Horsburgh MJ, McDowell PW, Mohamad SA, Stapleton MR, Acevedo J, Read RC, Day NP, Peacock SJ, Mond JJ, Kokai-Kun JF, Foster SJ. 2006. Identification of *in vivo*-expressed antigens of *Staphylococcus aureus* and their use in vaccinations for protection against nasal carriage. J Infect Dis 193:1098–1108. http://dx.doi.org/10.1086/501471.
- Burian M, Rautenberg M, Kohler T, Fritz M, Krismer B, Unger C, Hoffmann WH, Peschel A, Wolz C, Goerke C. 2010. Temporal expression of adhesion factors and activity of global regulators during establishment of *Staphylococcus aureus* nasal colonization. J Infect Dis 201: 1414–1421. http://dx.doi.org/10.1086/651619.
- Burian M, Wolz C, Goerke C. 2010. Regulatory adaptation of *Staphylococcus aureus* during nasal colonization of humans. PLoS One 5:e10040. http://dx.doi.org/10.1371/journal.pone.0010040.
- Jenkins A, Diep BA, Mai TT, Vo NH, Warrener P, Suzich J, Stover CK, Sellman BR. 2015. Differential expression and roles of *Staphylococcus aureus* virulence determinants during colonization and disease. mBio 6:e02272-14. http://dx.doi.org/10.1128/mBio.02272-14.
- Wertheim HF, Walsh E, Choudhurry R, Melles DC, Boelens HA, Miajlovic H, Verbrugh HA, Foster T, van Belkum A. 2008. Key role for clumping factor B in *Staphylococcus aureus* nasal colonization of humans. PLoS Med 5:e17. http://dx.doi.org/10.1371/journal.pmed.0050017.
- Winstel V, Xia G, Peschel A. 2014. Pathways and roles of wall teichoic acid glycosylation in *Staphylococcus aureus*. Int J Med Microbiol 304: 215–221. http://dx.doi.org/10.1016/j.ijmm.2013.10.009.
- Weidenmaier C, Kokai-Kun JF, Kristian SA, Chanturiya T, Kalbacher H, Gross M, Nicholson G, Neumeister B, Mond JJ, Peschel A. 2004. Role of teichoic acids in *Staphylococcus aureus* nasal colonization, a major risk factor in nosocomial infections. Nat Med 10:243–245. http://dx.doi.org/ 10.1038/nm991.
- Weidenmaier C, Kokai-Kun JF, Kulauzovic E, Kohler T, Thumm G, Stoll H, Götz F, Peschel A. 2008. Differential roles of sortase-anchored surface proteins and wall teichoic acid in *Staphylococcus aureus* nasal colonization. Int J Med Microbiol 298:505–513. http://dx.doi.org/10.1016/ j.ijmm.2007.11.006.
- 24. Baur S, Rautenberg M, Faulstich M, Grau T, Severin Y, Unger C, Hoffmann WH, Rudel T, Autenrieth IB, Weidenmaier C. 2014. A nasal epithelial receptor for *Staphylococcus aureus* WTA governs adhesion to epithelial cells and modulates nasal colonization. PLoS Pathog 10: e1004089. http://dx.doi.org/10.1371/journal.ppat.1004089.
- Brown S, Xia G, Luhachack LG, Campbell J, Meredith TC, Chen C, Winstel V, Gekeler C, Irazoqui JE, Peschel A, Walker S. 2012. Methicillin resistance in *Staphylococcus aureus* requires glycosylated wall teichoic acids. Proc Natl Acad Sci U S A 109:18909–18914. http:// dx.doi.org/10.1073/pnas.1209126109.
- Xia G, Maier L, Sanchez-Carballo P, Li M, Otto M, Holst O, Peschel A. 2010. Glycosylation of wall teichoic acid in *Staphylococcus aureus* by TarM. J Biol Chem 285:13405–13415. http://dx.doi.org/10.1074/ jbc.M109.096172.
- Xia G, Corrigan RM, Winstel V, Goerke C, Gründling A, Peschel A. 2011. Wall teichoic acid-dependent adsorption of staphylococcal siphovirus and myovirus. J Bacteriol 193:4006–4009. http://dx.doi.org/10.1128/ JB.01412-10.
- Kokai-Kun JF. 2008. The cotton rat as a model for *Staphylococcus aureus* nasal colonization in humans: cotton rat S. aureus nasal colonization model. Methods Mol Biol 431:241–254.
- 29. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. 1978. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol **93**:771–791.
- Niewiesk S, Prince G. 2002. Diversifying animal models: the use of hispid cotton rats (*Sigmodon hispidus*) in infectious diseases. Lab Anim 36: 357–372. http://dx.doi.org/10.1258/002367702320389026.
- 31. Kurokawa K, Jung DJ, An JH, Fuchs K, Jeon YJ, Kim NH, Li X, Tateishi K, Park JA, Xia G, Matsushita M, Takahashi K, Park HJ, Peschel A, Lee BL. 2013. Glycoepitopes of staphylococcal wall teichoic acid govern complement-mediated opsonophagocytosis via human serum antibody and mannose-binding lectin. J Biol Chem 288:30956–30968. http://dx.doi.org/10.1074/jbc.M113.509893.
- Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, Roosendaal R, Troelstra A, Box AT, Voss A, van der Tweel I, van Belkum A, Verbrugh HA, Vos MC. 2010. Preventing surgical-site infections in nasal carriers of *Staphylococcus aureus*. N Engl J Med 362: 9–17. http://dx.doi.org/10.1056/NEJMoa0808939.
- 33. Bae T, Schneewind O. 2006. Allelic replacement in Staphylococcus aureus

with inducible counter-selection. Plasmid 55:58-63. http://dx.doi.org/10.1016/j.plasmid.2005.05.005.

- 34. Monk IR, Shah IM, Xu M, Tan MW, Foster TJ. 2012. Transforming the untransformable: application of direct transformation to manipulate genetically *Staphylococcus aureus* and *Staphylococcus epidermidis*. mBio 3:e00277-11. http://dx.doi.org/10.1128/mBio.00277-11.
- 35. Winstel V, Liang C, Sanchez-Carballo P, Steglich M, Munar M, Broker BM, Penades JR, Nubel U, Holst O, Dandekar T, Peschel A, Xia G. 2013. Wall teichoic acid structure governs horizontal gene transfer between major bacterial pathogens. Nat Commun 4:2345. http://dx.doi.org/10.1038/ ncomms3345.
- 36. Brückner R. 1992. A series of shuttle vectors for Bacillus subtilis and

Escherichia coli. Gene 122:187–192. http://dx.doi.org/10.1016/0378 -1119(92)90048-T.

- 37. Harmsen D, Claus H, Witte W, Rothgänger J, Claus H, Turnwald D, Vogel U. 2003. Typing of methicillin-resistant *Staphylococcus aureus* in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 41:5442–5448. http:// dx.doi.org/10.1128/JCM.41.12.5442-5448.2003.
- Goerke C, Fluckiger U, Steinhuber A, Bisanzio V, Ulrich M, Bischoff M, Patti JM, Wolz C. 2005. Role of *Staphylococcus aureus* global regulators *sae* and *sigmaB* in virulence gene expression during device-related infection. Infect Immun 73:3415–3421. http://dx.doi.org/10.1128/IAI.73.6.3415 -3421.2005.